Yuekang Pharmaceutical: Subsidiary YKYY013 Injection Approved for Clinical Trials by National Medical Products Administration

Yuekang Pharmaceutical announced that its subsidiaries Yuekang Scientific Innovation and Hangzhou Tianlong recently obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for YKYY013 injection for the treatment of chronic hepatitis B virus infection. They will conduct Phase I clinical trials. This injection is a chemically synthesized double-stranded siRNA drug developed independently, and preclinical studies have shown significant HBV virus inhibition activity and good safety. It has also recently received a clinical trial approval letter from the US FDA. However, drug development involves long cycles, multiple stages, high risks, and other uncertainties, with no significant impact on short-term performance.